Patents Assigned to iNtRON Biotechnology, Inc.
  • Patent number: 12280081
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: April 22, 2025
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Eun Kyoung Oh, Geun Woo Lee, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 12274721
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: April 15, 2025
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Eun Kyoung Oh, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 12263196
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Grant
    Filed: October 19, 2023
    Date of Patent: April 1, 2025
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Eun Kyoung Oh, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 12114664
    Abstract: The present invention relates to a Siphoviridae bacteriophage STP-2 (Accession number: KCTC 12853BP) isolated from nature and characterized by having the ability to destroy Salmonella Typhimurium and having a genome represented by SEQ ID NO:1; and to a method for preventing and treating diseases caused by Salmonella Typhimurium using Siphoviridae bacteriophage STP-2 containing the same as an active ingredient.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: October 15, 2024
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Beom Seok Kim, Sang Hyeon Kang
  • Patent number: 11970700
    Abstract: The present invention relates to an intracellular expression enhancing genetic element, which enhances the intracellular expression of target protein encoded in RNA therapeutics such as mRNA vaccines and RNA medicines. In more detail, the present invention relates to the RNA molecule which has the genetic element capable of enhancing the intracellular expression of target protein encoded in RNA therapeutics delivered into cells; the plasmid used to synthesize the RNA molecule having the genetic element “E3”; the method for synthesizing RNA molecule having the genetic element “E3” using the plasmid and utilizing the synthesized RNA molecule as RNA therapeutics.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: April 30, 2024
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, An Sung Kwon, Se Hwan Kim, Sang Hyeon Kang
  • Patent number: 11701398
    Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: July 18, 2023
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Hyun Joo Im, Hyun Jin Yu, Beom Seok Kim, Geun Woo Lee, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 11679137
    Abstract: The present invention relates to Myoviridae bacteriophage Vib-PAP-4(Accession No. KCTC 13168BP), isolated from nature, which possesses ability to specifically kill Vibrio parahaemolyticus bacteria and has the genome represented by SEQ ID No: 1, and a method for preventing infection of Vibrio parahaemolyticus bacteria and treating infection of Vibrio parahaemolyticus baceteria, using a composition containing the bacteriophage as an effective ingredient.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: June 20, 2023
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Soon Hye Hwang, Sang Hyeon Kang
  • Patent number: 11679138
    Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-7 (Accession number: KCTC 13247BP) isolated from nature, which has the ability to kill Vibrio parahaemolyticus and has the genome represented by SEQ ID NO: 1, and a method for preventing or treating a disease caused by Vibrio parahaemolyticus using a composition containing the Myoviridae bacteriophage Vib-PAP-7 as an active ingredient.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 20, 2023
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Eun Ji Lee, Sang Hyeon Kang
  • Patent number: 11596659
    Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage Esc-COP-18 having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: March 7, 2023
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Hyun Joo Im, Hyun Jin Yu, Cheol Ahn, Tae Yeol Kim, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 11583565
    Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.
    Type: Grant
    Filed: April 4, 2020
    Date of Patent: February 21, 2023
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Hyun Joo Im, Ji Young Park, Hyun Jin Yu, Ji Yeong Seo, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 11548917
    Abstract: A pharmaceutical composition for treating Gram negative bacteria-associated infections includes an antibacterial protein that includes at least one selected from the group consisting of a protein having the amino acid sequence as set forth in SEQ ID NO: 1, a protein having the amino acid sequence as set forth in SEQ ID NO: 2, a protein having the amino acid sequence as set forth in SEQ ID NO: 3, a protein having the amino acid sequence as set forth in SEQ ID NO: 4, a protein having the amino acid sequence as set forth in SEQ ID NO: 5, a protein having the amino acid sequence as set forth in SEQ ID NO: 6, a protein having the amino acid sequence as set forth in SEQ ID NO: 7, and a protein having the amino acid sequence as set forth in SEQ ID NO: 8. A method of preparing the antibacterial protein is also disclosed.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: January 10, 2023
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jeong Won Park, Ji Hyun Kim, Saet Byeol Kim, Sang Hyeon Kang
  • Patent number: 11529406
    Abstract: The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: December 20, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Hee Jeong Shin, Sang Hyeon Kang
  • Patent number: 11497216
    Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-4 (accession number: KCTC 13166BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-4 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-4 as an active ingredient.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: November 15, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Hee Jeong Shin, Sang Hyeon Kang
  • Patent number: 11492378
    Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP), which has the ability to kill Enterococcus faecium and an amino acid sequence represented by SEQ ID NO: 2, a pharmaceutical composition containing the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium using the pharmaceutical composition.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: November 8, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang
  • Patent number: 11458177
    Abstract: The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by administering the pharmaceutical composition.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: October 4, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Sang Hyeon Kang
  • Patent number: 11457635
    Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-3 (accession number: KCTC 13165BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-3 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-3 as an active ingredient.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: October 4, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Hee Jeong Shin, Sang Hyeon Kang
  • Patent number: 11452757
    Abstract: A pharmaceutical composition for treating Gram negative bacteria-associated infections includes an antibacterial protein that includes at least one selected from the group of a protein having the amino acid sequence as set forth in SEQ ID NO: 1, a protein having the amino acid sequence as set forth in SEQ ID NO: 2, a protein having the amino acid sequence as set forth in SEQ ID NO: 3, a protein having the amino acid sequence as set forth in SEQ ID NO: 4, a protein having the amino acid sequence as set forth in SEQ ID NO: 5, a protein having the amino acid sequence as set forth in SEQ ID NO: 6, a protein having the amino acid sequence as set forth in SEQ ID NO: 7, and a protein having the amino acid sequence as set forth in SEQ ID NO: 8. A method of preparing the antibacterial protein is also disclosed.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: September 27, 2022
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jeong Won Park, Ji Hyun Kim, Saet Byeol Kim, Sang Hyeon Kang
  • Patent number: 11351210
    Abstract: The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcus garvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcus garvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: June 7, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Hyun Min Song, Sang Hyeon Kang
  • Patent number: 11324841
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MEI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: May 10, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Patent number: 11229677
    Abstract: A method of treating staphylococcal infections includes administering to a subject an effective amount of an antibacterial composition having a broad bactericidal activity. The antibacterial composition includes a first antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 1 and/or a second antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 2.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: January 25, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Gi Mo Jung, Sang Hyeon Kang